| First Author | Zhu M | Year | 2023 |
| Journal | Cancer Cell | Volume | 41 |
| Issue | 10 | Pages | 1731-1748.e8 |
| PubMed ID | 37774698 | Mgi Jnum | J:341369 |
| Mgi Id | MGI:7538747 | Doi | 10.1016/j.ccell.2023.09.006 |
| Citation | Zhu M, et al. (2023) Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell 41(10):1731-1748.e8 |
| abstractText | The role of tumor mutational burden (TMB) in shaping tumor immunity is a key question that has not been addressable using genetically engineered mouse models (GEMMs) of lung cancer. To induce TMB in lung GEMMs, we expressed an ultra-mutator variant of DNA polymerase-E (POLE)(P286R) in lung epithelial cells. Introduction of Pole(P286R) allele into Kras(G12D) and Kras(G12D); p53(L/L) (KP) models significantly increase their TMB. Immunogenicity and sensitivity to immune checkpoint blockade (ICB) induced by Pole is partially dependent on p53. Corroborating these observations, survival of NSCLC patients whose tumors have TP53(truncating) mutations is shorter than those with TP53(WT) with immunotherapy. Immune resistance is in part through reduced antigen presentation and in part due to mutational heterogeneity. Total STING protein levels are elevated in Pole mutated KP tumors creating a vulnerability. A stable polyvalent STING agonist or p53 induction increases sensitivity to immunotherapy offering therapeutic options in these polyclonal tumors. |
